If Novo Nordisk can't cure diabetes, someone else might – "that would be pretty embarrassing"
Novo Nordisk’s chief executive Lars Fruergaard Jørgensen acknowledges that stem cell therapies could end up eroding Novo Nordisk’s core business: Selling insulin.
By MarketWire, translated by Daniel Pedersen
Danish drugmaker Novo Nordisk has spent a quarter of a century – also one fourth of its existence – on researching the possibility of using stem cell therapies against diabetes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
